Evidence map›Paper›PMID 37118530›Full record

ArticleChinese journal of integrative medicine2024

Clean-DM1, a Korean Polyherbal Formula, Improves High Fat Diet-Induced Diabetic Symptoms in Mice by Regulating IRS/PI3K/AKT and AMPK Expressions in Pancreas and Liver Tissues.

Piao Wang, Yi Liu, Seok Yong Kang, Chenzi Lyu, Xiang Han, Tianjun Ho, Kyung Jae Lee, Xianglong Meng, Yong-Ki Park, Hyo Won Jung

Abstract read
PubMed Publisher
In one paragraph

Article in Chinese journal of integrative medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. The mechanism and application ofFrontiers in endocrinology · 2025
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Piao WangDepartment of Herbology, College of Korean Medicine, Dongguk University, Gyeongju, 38066, Korea.
Yi LiuDepartment of Herbology, College of Korean Medicine, Dongguk University, Gyeongju, 38066, Korea.
Seok Yong KangDepartment of Herbology, College of Korean Medicine, Dongguk University, Gyeongju, 38066, Korea.
Chenzi LyuDepartment of Herbology, College of Korean Medicine, Dongguk University, Gyeongju, 38066, Korea.
Xiang HanShanxi Key Laboratory of Traditional Herbal Medicines Processing, Shanxi University of Chinese Medicine, Jinzhong, Shanxi Province, 030619, China.
Tianjun HoDepartment of Herbology, College of Korean Medicine, Dongguk University, Gyeongju, 38066, Korea.
Kyung Jae LeeDepartment of Herbology, College of Korean Medicine, Dongguk University, Gyeongju, 38066, Korea.
Xianglong MengShanxi Key Laboratory of Traditional Herbal Medicines Processing, Shanxi University of Chinese Medicine, Jinzhong, Shanxi Province, 030619, China.
Yong-Ki ParkDepartment of Herbology, College of Korean Medicine, Dongguk University, Gyeongju, 38066, Korea.
Hyo Won JungDepartment of Herbology, College of Korean Medicine, Dongguk University, Gyeongju, 38066, Korea. tenzing2@hanmail.net.
Dongguk University · KRShanxi University · CNEwha Womans University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the effects of Clean-DM1 (C-DM1), a polyherbal formulation of Radix Scrophulariae, Radix Astragali, Rhizoma Atractylodis, and Radix Salviae Miltiorrhizae, on high-fat diet (HFD)-induced diabetes mice.

methodsThe information about active components of C-DM1 extract and molecular mechanism was obtained from network pharmacology analysis. Main compounds of C-DM1 extract by high performance liquid chromatography-mass spectrometry (HPLC-MS) analysis were conducted for quality control. For in vivo study, mice were induced diabetes by HFD for 12 weeks. The mice in the normal group (Nor) were maintained with a regular diet and treated with saline by gavage. The HFD model mice were randomly divided into 3 groups, including a HFD diabetic model group, a C-DM1 extract-administered group (C-DM1, 500 mg/kg), and metformin-administered groups (Met, 500 mg/kg), 8 mice in each group. Food intake, body weight (BW), and fasting blood glucose (FBG) levels were recorded weekly for 4 weeks. After 4 weeks of treatment, alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood glucose, low-density lipoprotein cholesterol (LDL-C) were determined using an automated clinical chemistry analyzer, and homeostatic model for assessing insulin resistance (HOMA-IR) levels and oral glucose tolerance test (OGTT) were detected. The histopathological changes of liver and pancreatic tissues were observed by hematoxylin-eosin staining. Insulin receptor substrate (IRS)/phosphatidylinositol 3 kinase (PI3K)/ protein kinase B (AKT) and adenosine 5'-monophosphate-activated protein kinase (AMPK) expressions in liver and pancreas tissues were detected by Western blot analysis.

resultsHPLC-MS identified dihydroisotanshinone, dihydroisotanshinone I, cryptotanshinone, harpagoside, and atractyloside A in C-DM1 extract. The administration of C-DM1 extract significantly decreased body weight, calorie intake, and the levels of blood glucose and insulin in the diabetic mice (P<0.05 or P<0.01). The C-DM1 extract administration improved the impaired glucose tolerance and insulin resistance in the diabetic mice and significantly decreased the levels of LDL-C, ALT and AST (P<0.01). The C-DM1 extract inhibited the histopathological changes of fatty liver and hyperplasia of pancreatic islets in the diabetic mice. The C-DM1 extract significantly increased the phosphorylation of IRS, AKT, and AMPK and the expression of PI3K in pancreas and liver tissues (P<0.05 or P<0.01), which was consistent with the analysis results of network pharmacology.

conclusionC-DM1 extract improved diabetes symptoms in long-term HFD-induced mice by regulation of IRS/PI3K/AKT and AMPK expressions in pancreas and liver tissues, suggesting that C-DM1 formulation may help prevent the progression of T2DM.

Indexed as

Diabetes Mellitus, ExperimentalInsulin ResistanceAMP-Activated Protein KinasesAnimalsBlood GlucoseBody WeightCholesterol, LDLDiet, High-FatInsulin Receptor Substrate ProteinsLiverMicePancreasPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRepublic of KoreaAMP-Activated Protein KinasesBlood GlucoseCholesterol, LDLInsulin Receptor Substrate ProteinsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktadenosine 5′-monophosphate-activated protein kinaseherbal formulationhigh-fat diethigh performance liquid chromatography-mass spectrometry analysisinsulin receptor substrate/phosphatidylinositol 3 kinase/protein kinase Bnetwork pharmacologytype 2 diabetes mellitus

Identifiers

PMID37118530
OpenAlexW4367301963

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.